JPMorgan cuts Arkema stock rating to underweight, slashes PT

Published 27/03/2025, 07:50
JPMorgan cuts Arkema stock rating to underweight, slashes PT

On Thursday, JPMorgan analysts downgraded Arkema SA (OTC:ARKAY) (AKE:FP) (OTC: ARKAF) stock from ’Neutral’ to ’Underweight,’ significantly reducing the price target to EUR 68.50 from EUR 92.00. The revision comes as the firm adjusted its expectations for the company’s future earnings before interest, taxes, depreciation, and amortization (EBITDA) and earnings before interest and taxes (EBIT).

The analysts reduced their forecast for Arkema (EPA:AKE)’s adjusted EBITDA in fiscal years 2025 and 2026 by 4% and 6%, respectively. These new estimates fall 6% and 9% short of the Bloomberg consensus. Similarly, the forecast for adjusted EBIT in the same years was cut by 9% and 11%, which is 9% and 15% below the consensus.

According to JPMorgan, if Arkema’s historical seasonality is considered, the implied adjusted EBITDA and EBIT for fiscal year 2025 would be approximately €1.32 billion and €0.65 billion, respectively. These figures are about 18% and 30% below the market consensus.

Despite the fact that Arkema’s valuation based on fiscal years 2026 and 2027 enterprise value to EBITDA multiples of around 6x, which is below the long-term median of approximately 7x, and the price to earnings (P/E) ratio for fiscal years 2025 and 2026 of 10-11x, below the long-term median of 12x, the shares are considered inexpensive. Furthermore, the firm’s estimated free cash flow (FCF) yield for the same period is around 7%.

However, JPMorgan anticipates that the potential for significant reductions to consensus estimates, the impact of a declining fluorogases business which could see approximately 10% and 20% cuts to fiscal year 2025 adjusted EBITDA and FCF, and the possibility of more return on invested capital (ROIC) dilutive acquisitions, will likely keep the valuation low. Arkema’s post-tax ROIC is already projected to be low at 5% and 6% excluding goodwill for 2025. These factors lead JPMorgan to predict that Arkema shares will underperform in the foreseeable future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.